PWMG
INDV icon

Prestige Wealth Management Group’s Indivior Pharmaceuticals INDV Stock Holding History

Prestige Wealth Management Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$903 Buy
22
+15
+214% +$544 ﹤0.01% 931
2026
Q1 		$214 Buy
+7
New +$231 ﹤0.01% 1066

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prestige Wealth Management Group's INDV Position: Q2 2026 in Review

Prestige Wealth Management Group increased its Indivior Pharmaceuticals (INDV) stake by 214% in Q2 2026, buying an estimated $544 and bringing the position to 22 shares worth $903. The position accounts for ﹤0.01% of the portfolio, ranked #931.

Prestige Wealth Management Group first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Prestige Wealth Management Group held 22 shares of Indivior Pharmaceuticals worth $903 as of Q2 2026.
  • Prestige Wealth Management Group bought 15 Indivior Pharmaceuticals shares in Q2 2026, an estimated $544.
  • Indivior Pharmaceuticals made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #931 holding.
  • Prestige Wealth Management Group first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.